HomeInvestors & MediaNews
- The company will keep developing Innovative BsAb-based biopharmaceuticals
ABL Bio (CEO Sang Hoon Lee), a company that specializes in bispecific antibodies, announced that it received an award in the ‘Most Promising Biologics Drug Pipeline’ category at the Korea Biopharma Excellence Awards 2024 hosted by IMAPAC specialized in bio industry-related events.
The awards ceremony was carried out on the 13th as one of the programs within the Biologics Manufacturing Korea 2024 & Vaccine World East Asia 2024 conference that was held in Songdo, Incheon, which hosted over 300 industry insiders.
ABL Bio is a bio company that develops immunotherapy using the 4-1BB-based BsAb platform ‘Grabody-T’, as well as neurodegenerative disease treatment that applies the Blood-Brain Barrier (BBB) shuttle platform, ‘Grabody-B’. Currently, the development of immunotherapy drugs ABL503 (ragistomig), ABL111 (givastomig), ABL103, and ABL105 in phase 1 clinical trials is underway, and in January 2022, an exclusive collaboration and worldwide license agreement with Sanofi worth $1.06B for ABL301, a treatment for Parkinson’s disease, was signed.
Recently, it has focused on developing next-generation modality bispecific ADCs that can improve the safety and efficacy of existing monospecific ADCs, with the goal of submitting Investigational New Drug applications (INDs) for at least three pipelines by 2025.
Sang Hoon Lee, CEO of ABL Bio, states, “We are very pleased to have won the Most Promising Biopharmaceutical Pipeline category. This award ceremony was a good opportunity to once again promote the technologies of the bispecific antibodies and ADC pipelines that ABL Bio is developing. In addition to the development of existing BsAb immunotherapy drugs and degenerative brain disease treatments, ABL Bio is developing new Bispecific ADC treatments to take this further into the future. We plan to accelerate our development of bispecific ADCs to dominate the global bispecific ADC market, which is still in its early stages. Please look forward to ABL Bio’s continued efforts to develop innovative biopharmaceuticals.”
About ABL Bio
ABL Bio is developing various clinical and non-clinical assets based on its bispecific antibody platform ‘Grabody’. More than 15 clinical projects for over 7 pipelines, including ABL001, ABL111, ABL503, ABL105, ABL202, ABL301, and ABL103, are underway for different indications in various countries, including the United States, China, Australia, and Korea. In the case of ABL001, the U.S. Food and Drug Administration (FDA) recently granted Fast Track designation to support the rapid development of this new drug candidate. Meanwhile, ABL Bio is preparing to initiate clinical trials for ABL104. In addition, ABL Bio is continuously researching and developing several other product candidates, including bispecific antibody-drug conjugates (ADCs).
Note: this is a translated version of the original Korean language document, prepared and provided solely for readers’ convenience. In case of any discrepancy or dispute, the Korean document prevails.